TREATMENT FOR ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION: PROGRESS AND PERSPECTIVES
- Authors: Gilyarov M1, Novikova N1, Ivanov A1, Syrkin A1, Gilyarov M2, Novikova N2, Ivanov A2, Syrkin A2
-
Affiliations:
- Sechenov Moscow Medical Academy
- Issue: Vol 20, No 3 (2009)
- Pages: 5-8
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115290
- ID: 115290
Cite item
Abstract
About the authors
M Gilyarov
Email: gilarov@rambler.ru <mailto:gilarov@rambler.ru>
N Novikova
A Ivanov
A Syrkin
M Gilyarov
Sechenov Moscow Medical AcademySechenov Moscow Medical Academy
N Novikova
Sechenov Moscow Medical Academy; Sechenov Moscow Medical Academy
A Ivanov
Sechenov Moscow Medical AcademySechenov Moscow Medical Academy
A Syrkin
Sechenov Moscow Medical Academy; Sechenov Moscow Medical Academy
References
- Abdel-Latif A. et al. Adult Bone Marrow-Derived Cells for Cardiac Repair // Arch. Intern. Med. - 2007; 167: 989-997.
- Boersma E. et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour // Lancet. -1996; 348: 771-775.
- Chen J., Normand SI. Myocardial infarction and quality of care // CMAJ.-2008; 21; 179: 875-876.
- De Luca G. et al. Time Delay to Treatment and Mortality in Primary Angioplasty for Acute Myocardial Infarction: Every Minute of Delay Counts // Circulation. - 2004; 109:1223-1225.
- Gersh B. J. et al. Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Is the Slope of the Curve the Shape of the Future? // JAMA. - 2005; 293: 979-986.
- Giraldez R.R., Nicolau J.C., Corbalan R. et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis // Eur. Heart. J. - 2007; 28:1566-1573.
- International Experts Workshop on Early Treatment Strategies for Acute Myocardial Infarction. Budapest, July 4-6, 2008. <http://www.metalyse>.com/img/ download/ mi_news_budapest08.pdf 8. Kent et al. Comparison of Mortality Benefit of Immediate Thrombolytic Therapy Versus Delayed Primary Angioplasty for Acute Myocardial Infarction
- // Am. J. Cardiol. - 2007; 99: 1384-1388.
- Peters R.J., Joyner С, Bassand J.P. et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial // Eur. Heart. J. - 2008; 29: 324-331.
- Steg et al. Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty: Data From the CAPTIM Randomized Clinical Trial // Circulation. - 2003; 108: 2851-2856.
- Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) <http://>www.cardiosource.com/ <http://www.cardiosource.com/>clinicaltrials/trial.asp?triallD=1661
- The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation // Eur. Heart J. - 2008; 29: 2909-2945.
- The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction // Lancet. - 2001; 358:605-613.
- Wallentin L, Goldstein P., Armstrong P.W. et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction // Circulation. - 2003; 108:135-142.
- White H.D., Braunwald E., Murphy S.A. et al. Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25 // Eur. Heart. J. - 2007; 28: 1066-1071.